T

TTK Healthcare Ltd
BSE:507747

Watchlist Manager
TTK Healthcare Ltd
BSE:507747
Watchlist
Price: 955 INR -0.58% Market Closed
Market Cap: ₹13.5B

Relative Value

The Relative Value of one TTKHEALTH stock under the Base Case scenario is 1 014.47 INR. Compared to the current market price of 955 INR, TTK Healthcare Ltd is Undervalued by 6%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

TTKHEALTH Relative Value
Base Case
1 014.47 INR
Undervaluation 6%
Relative Value
Price
T
Worst Case
Base Case
Best Case

Multiples Across Competitors

TTKHEALTH Competitors Multiples
TTK Healthcare Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
TTK Healthcare Ltd
BSE:507747
13.6B INR 1.6 22.6 16.7 24.6
US
Eli Lilly and Co
NYSE:LLY
978.7B USD 16.5 53.3 35.8 38.3
US
Johnson & Johnson
NYSE:JNJ
547.3B USD 5.8 20.4 14.2 17.4
CH
Roche Holding AG
SIX:ROG
280B CHF 4.6 29.7 12.6 14.7
UK
AstraZeneca PLC
LSE:AZN
215.1B GBP 5 31.2 20.3 29.7
CH
Novartis AG
SIX:NOVN
223.5B CHF 5.1 19.7 15.8 20.4
US
Merck & Co Inc
NYSE:MRK
273B USD 4.3 14.4 10.2 12.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.2 15.8 11 12.7
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
150.2B USD 2.4 15.3 7.7 10.5
FR
Sanofi SA
PAR:SAN
97B EUR 1.7 8.2 7.7 7.7
P/E Multiple
Earnings Growth PEG
IN
T
TTK Healthcare Ltd
BSE:507747
Average P/E: 23.1
22.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.3
54%
1
US
Johnson & Johnson
NYSE:JNJ
20.4
6%
3.4
CH
Roche Holding AG
SIX:ROG
29.7
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.2
38%
0.8
CH
Novartis AG
SIX:NOVN
19.7
17%
1.2
US
Merck & Co Inc
NYSE:MRK
14.4
14%
1
DK
Novo Nordisk A/S
CSE:NOVO B
15.8
2%
7.9
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.3
27%
0.6
FR
Sanofi SA
PAR:SAN
8.2
1%
8.2
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
T
TTK Healthcare Ltd
BSE:507747
Average EV/EBITDA: 45.2
16.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.8
34%
1.1
US
Johnson & Johnson
NYSE:JNJ
14.2
2%
7.1
CH
Roche Holding AG
SIX:ROG
12.6
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
20.3
10%
2
CH
Novartis AG
SIX:NOVN
15.8
6%
2.6
US
Merck & Co Inc
NYSE:MRK
10.2
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11
1%
11
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.7
0%
N/A
FR
Sanofi SA
PAR:SAN
7.7
8%
1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
T
TTK Healthcare Ltd
BSE:507747
Average EV/EBIT: 95.7
24.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.3
37%
1
US
Johnson & Johnson
NYSE:JNJ
17.4
6%
2.9
CH
Roche Holding AG
SIX:ROG
14.7
6%
2.5
UK
AstraZeneca PLC
LSE:AZN
29.7
23%
1.3
CH
Novartis AG
SIX:NOVN
20.4
12%
1.7
US
Merck & Co Inc
NYSE:MRK
12.1
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.7
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.5
7%
1.5
FR
Sanofi SA
PAR:SAN
7.7
6%
1.3